MedTrace Logo

Epidemiological EMESIS-Registry

NCT00911222 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1035

Last updated 2014-12-24

No results posted yet for this study

Summary

The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.

Conditions

  • Antiemetic Therapy

Interventions

OTHER

non-interventional

non-interventional

Sponsors & Collaborators

  • Arbeitsgemeinschaft fur Internistische Onkologie

    collaborator OTHER

  • ASORS

    collaborator UNKNOWN

  • Arbeitskreis Klinische Studien

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Jan Schröder, Dr. med. / MD · Praxis für Hämatologie und Onkologie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-05-31
Completion
2009-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00911222 on ClinicalTrials.gov